Linagliptin appeared to improve HOMA-IS, HOMA-β, insulinogenic index and oral disposition index in low GLP-1 prediabetes although the LS-mean changes from baseline in these indices did not reach statistical significance. This evidence concerns the gene GCG and prediabetes syndrome.